10 research outputs found
Promotion of Prescription Drugs to Consumers and Providers, 2001â2010
Background: Pharmaceutical firms heavily promote their products and may have changed marketing strategies in response to reductions in new product approvals, restrictions on some forms of promotion, and the expanding role of biologic therapies.
Methods: We used descriptive analyses of annual cross-sectional data from 2001 through 2010 to examine direct-to-consumer advertising (DTCA) (Kantar Media) and provider-targeted promotion (IMS Health and SDI), including: (1) inflation-adjusted total promotion spending (36.1 billion (13.4% of sales). By 2010 it had declined to 370 million (8.8% of sales) spent on promotion, top biologics were promoted less, with only $33 million (1.4% of sales) spent per product. Little change occurred in the composition of promotion between primary care physicians and specialists from 2001â2010. Conclusions: These findings suggest that pharmaceutical companies have reduced promotion following changes in the pharmaceutical pipeline and patent expiry for several blockbuster drugs. Promotional strategies for biologic drugs differ substantially from small molecule therapies
No More Free Drug Samples?
Susan Chimonas and Jerome Kassirer argue that giving out âfreeâ drug samples is not effective in improving drug access for the indigent, does not promote rational drug use, and raises the cost of care
A bioassay method for formulation testing and residue studies of sulfonylurea and sulfonanylide herbicides
General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study
Understanding the effects of pharmaceutical promotion: a neural network approach guided by genetic algorithm-partial least squares
Antibiotic, Genetic algorithm, Partial least squares, Neural networks, Optimization, Physiciansâ prescribing behavior, Pharmaceutical promotion, Promotional effectiveness, Promotion effects, Promotional spending,